Why is it worth using rosuvastatin and ezetimibe in one tablet? Review article
Article Sidebar
Published:
Dec 31, 2023
Keywords:
ezetimibe, rosuvastatin
Main Article Content
Abstract
Statin and ezetimibe treatment is the backbone of hypercholesterolemia therapy. The combination of statin with ezetimibe makes it possible to lower LDL cholesterol by 65% from baseline. Unfortunately, due to, among other reasons, lack of adherence and frequent skipping of medication, there is still a large group of patients who do not achieve the goals of hypolipemic therapy. Therefore, simplifying the treatment regimen and combining statin and ezetimibe into a single pill may be the key to success in lowering LDL cholesterol and, moreover, lowering patients’ cardiovascular risk.
Article Details
How to Cite
Dobrowolski, P. (2023). Why is it worth using rosuvastatin and ezetimibe in one tablet?. Medycyna Faktow (J EBM), 16(4(61), 384-386. https://doi.org/10.24292/01.MF.0423.15
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mach F, Baigent C, Catapano AL et al.; Group ESCSD. 2019 esc/eas guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41: 111-88.
2. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation. 2003; 107: 2409-15.
3. Katzmann JL, Sorio-Vilela F, Dornstauder E et al. Non-statin lipid-lowering therapy over time in very-high-risk patients: Effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on ldl-c. Clin Res Cardiol. 2022; 111: 243-52.
4. Tsioufis K, Kreutz R, Sykara G et al. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: A rapid evidence assessment of recent literature. J Hypertens. 2020; 38: 1016-28.
5. Mackenzie IS, Rogers A, Poulter NR et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the uk (time study): A prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022; 400: 1417-25.
2. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation. 2003; 107: 2409-15.
3. Katzmann JL, Sorio-Vilela F, Dornstauder E et al. Non-statin lipid-lowering therapy over time in very-high-risk patients: Effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on ldl-c. Clin Res Cardiol. 2022; 111: 243-52.
4. Tsioufis K, Kreutz R, Sykara G et al. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: A rapid evidence assessment of recent literature. J Hypertens. 2020; 38: 1016-28.
5. Mackenzie IS, Rogers A, Poulter NR et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the uk (time study): A prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022; 400: 1417-25.